LUF7244, an allosteric modulator/activator of Kv11.1 channels, counteracts dofetilide‐induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model

Kv11.1 (hERG) channel blockade is an adverse effect of many drugs and lead compounds, associated with lethal cardiac arrhythmias. LUF7244 is a negative allosteric modulator/activator of Kv11.1 channels that inhibits early afterdepolarizations in vitro. We tested LUF7244 for antiarrhythmic efficacy and potential proarrhythmia in a dog model.

• Publication year

  2019

• Venue

  British Journal of Pharmacology

• Publication date

  2019-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bph.14798PMID 31339551PMCID 6780032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LUF7244, an allosteric modulator/activator of Kv11.1 channels, counteracts dofetilide‐induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model

  2019cited by this paper
• Selective late sodium current inhibitor GS‐458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia

  2018cited by this paper
• Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo

  2018influential reference
• Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

  2018cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltage‐gated ion channels

  2017cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  2017cited by this paper
• Torsade de pointes arrhythmias arise at the site of maximal heterogeneity of repolarization in the chronic complete atrioventricular block dog

  2016cited by this paper
• A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells

  2016influential reference
• Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias

  2016influential reference
• Beat-to-Beat Variability in Preload Unmasks Latent Risk of Torsade de Pointes in Anesthetized Chronic Atrioventricular Block Dogs.

  2016cited by this paper
• New potential binding determinant for hERG channel inhibitors

  2016cited by this paper
• Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.

  2014cited by this paper
• Sex differences in the mechanisms underlying long QT syndrome.

  2014cited by this paper
• HERG1 channel agonists and cardiac arrhythmia.

  2014cited by this paper
• ICA-105574 Interacts with a Common Binding Site to Elicit Opposite Effects on Inactivation Gating of EAG and ERG Potassium Channels

  2013cited by this paper
• Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts.

  2013influential reference
• Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.

  2013cited by this paper
• Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo.

  2012cited by this paper
• Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel

  2012cited by this paper
• Identification and Characterization of a Compound That Protects Cardiac Tissue from Human Ether-à-go-go-related Gene (hERG)-related Drug-induced Arrhythmias*

  2012cited by this paper
• Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines

  2011cited by this paper
• Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development

  2010cited by this paper
• SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers

  2010cited by this paper
• Pharmacological Removal of Human Ether-à-go-go-Related Gene Potassium Channel Inactivation by 3-Nitro-N-(4-phenoxyphenyl) Benzamide (ICA-105574)

  2010cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields

  2009cited by this paper
• Pharmacological Removal of hERG Potassium Channel Inactivation by ICA-105574

  2009cited by this paper
• Electrophysiologic characterization of a novel hERG channel activator.

  2009cited by this paper
• The canine model with chronic, complete atrio-ventricular block.

  2008cited by this paper
• 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels

  2008cited by this paper
• In Vivo Effects of the IKr Agonist NS3623 on Cardiac Electrophysiology of the Guinea Pig

  2008cited by this paper
• CHARMM‐GUI: A web‐based graphical user interface for CHARMM

  2008cited by this paper
• hERG1 channel activators: a new anti-arrhythmic principle.

  2008cited by this paper
• Canonical sampling through velocity rescaling.

  2007cited by this paper
• Inhibition of cardiomyocyte automaticity by electrotonic application of inward rectifier current from Kir2.1 expressing cells

  2006cited by this paper
• hERG potassium channels and cardiac arrhythmia

  2006cited by this paper
• Activation of Human ether-a-go-go-Related Gene Potassium Channels by the Diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643)

  2006cited by this paper
• Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity

  2005cited by this paper
• Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.

  2005cited by this paper
• Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel

  2005cited by this paper
• Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog.

  2003cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.

  2001cited by this paper
• Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

  2001cited by this paper
• HERG Channel Dysfunction in Human Long QT Syndrome

  1998cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• LINCS: A linear constraint solver for molecular simulations

  1997cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems

  1993cited by this paper
• Polymorphic transitions in single crystals: A new molecular dynamics method

  1981cited by this paper

• KCNH3 Loss-of-Function Variant Associated with Epilepsy and Neurodevelopmental Delay Enhances Kv12.2 Channel Inactivation

  2025cites this paper
• Development of new Kir2.1 channel openers from propafenone analogues

  2024influential citation
• Recording ten-fold larger IKr conductances with automated patch clamping using equimolar Cs+ solutions

  2024cites this paper
• Pro-Arrhythmic Potential of Accumulated Uremic Toxins Is Mediated via Vulnerability of Action Potential Repolarization

  2023cites this paper
• Chronic Propafenone Application Increases Functional KIR2.1 Expression In Vitro

  2023cites this paper
• The ERG1 K+ Channel and Its Role in Neuronal Health and Disease

  2022cites this paper
• Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: A review

  2022cites this paper
• Cardiac hERG K+ Channel as Safety and Pharmacological Target.

  2021cites this paper
• The canine chronic atrioventricular block model in cardiovascular preclinical drug research

  2021cites this paper
• The Concept of Receptor and Molecule Interaction in Drug Discovery and Development

  2021cites this paper
• An Update on the Structure of hERG

  2020cites this paper
• Targeting the Kv11.1 (hERG) channel with allosteric modulators. Synthesis and biological evaluation of three novel series of LUF7346 derivatives.

  2020cites this paper
• Drug Development in Channelopathies: Allosteric Modulation of Ligand-Gated and Voltage-Gated Ion Channels.

  2020cites this paper
• Development and validation of HPTLC method for estimation of dofetilide in pharmaceutical dosage form and determination of its degradation profile by MS-MS method

  2020cites this paper
• Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease

  2020cites this paper
• Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2 KCNH2 (hERG) Mutations and Identifying New Patients

  2020cites this paper
• LUF7244 plus Dofetilide Rescues Aberrant Kv11.1 Trafficking and Produces Functional IKv11.1

  2020influential citation
• LUF7244, an allosteric modulator/activator of Kv11.1 channels, counteracts dofetilide‐induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model

  2019cites this paper